Hussein H. M. Al-Masoudi, Mohammad N. AL-Baiati, Karim Akbari Dilmaghani
Perinatal Journal - 2026;34(1):62-73
In this study, we embarked on an intriguing journey to create a groundbreaking nano graft copolymer -Paracetamol drug composite, and we eagerly assessed its anticancer potential against the MCF -7 breast cancer cell line. The creation of our nano copolymer was a result of a poly condensation reaction that cleverly combined 2.0 moles of glycerol with 4.0 moles of phthalic anhydride. We left no stone unturned in confirming its structure, utilizing an array of techniques like FT -IR, ¹H NMR, ¹³C NMR, and various imaging methods including X -ray diffraction (XRD), transmission electron microscopy (TEM), and atomic force microscopy (AFM) to ensure its integrity. By further functionalizing the copolymer with 1. 0 mole of Paracetamol, we crafted a nano drug composite that was subjected to the same rigorous characterization methods. We didn't stop there; molecular docking analysis was performed to dive deeper into the interactions between our composite and crucial proteins linked to breast cancer. The results were promising, revealing favorable binding interactions that hinted at a possible therapeutic mechanism at play. When we turned to in vitro cytotoxicity assays against MCF -7 cells, the results were quite remarkable -an impressive IC?? value of 52.46 µg/mL showcased the significant anticancer activity of our creation. These findings paint a vivid picture of the potential that our synthesized nano drug composite holds as a targeted therapy for breast cancer, setting the stage for future research and development in this vital area.
